SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Akari Therapeutics, Plc.

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

00972G405

(CUSIP Number)

06/02/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP Number(s):

00972G405

Names of Reporting Persons

MMCAP International Inc. SPC

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,000,000,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,000,000,000.00

Aggregate Amount Beneficially Owned by Each Reporting Person

8,000,000,000.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

8.0 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: The Reporting Person owns 100,000 American Depository Shares (NASDAQ: AXTX) of the Issuer, each convertible into 80,000 Ordinary Shares, par value $0.000000005, of the Issuer

SCHEDULE 13G

CUSIP Number(s):

00972G405

Names of Reporting Persons

MM Asset Management Inc.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

ONTARIO, CANADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 8,000,000,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 8,000,000,000.00

Aggregate Amount Beneficially Owned by Each Reporting Person

8,000,000,000.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

8.0 %

Type of Reporting Person (See Instructions)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Akari Therapeutics, Plc.

(b)

Address of issuer's principal executive offices:

401 E. Jackson Street, Suite 3300, Tampa, FL 33602

Item 2.

(a)

Name of person filing:

i) MMCAP International Inc. SPC ii) MM Asset Management Inc.

(b)

Address or principal business office or, if none, residence:

i) c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, P. O. Box 1348, Grand Cayman KY1-1108, Cayman Islands ii) 161 Bay Street, TD Canada Trust Tower, Suite 2240, Toronto, Ontario M5J 2S1 Canada

(c)

Citizenship:

i) Cayman Islands ii) Ontario, Canada

(d)

Title of class of securities:

Ordinary Shares

(e)

CUSIP Number(s):

00972G405

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

8,000,000,000 Represents 100,000 American Depository Shares, each convertible into 80,000 Ordinary Shares

(b)

Percent of class:

8.0% Percent of class calculated on a partially-diluted basis using 91,567,009,533 Ordinary Shares, par value $0.000000005, outstanding as of March 31, 2026, as reported on the Issuer's 10-Q filed with the Securities and Exchange Commission on May 19, 2026.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or to direct the vote:

8,000,000,000

(iii) Sole power to dispose or to direct the disposition of:

(iv) Shared power to dispose or to direct the disposition of:

8,000,000,000

Item 5.

Ownership of 5 Percent or Less of a Class.

Not Applicable

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MMCAP International Inc. SPC

Signature:	Ulla Vestergaard
Name/Title:	Director
Date:	06/08/2026

MM Asset Management Inc.

Signature:	Hillel Meltz
Name/Title:	President
Date:	06/08/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

SEC Form SCHEDULE 13G filed by Akari Therapeutics plc